The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)
The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Deprenyl/Selegiline (DEP), created by Joseph Knoll in the 1960s, registered in more than 60 countries to treat Parkinson’s disease, Alzheimer’s disease, major depressive disorder; and used as an anti-aging drug, achieved its place in research and therapy as the first selective inhibitor of B-type monoamine oxidase (MAO-B). The demonstration that th...
Alternative Titles
Full title
The significance of selegiline/(−)-deprenyl after 50 years in research and therapy (1965–2015)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1837335941
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1837335941
Other Identifiers
ISSN
1359-4184
E-ISSN
1476-5578
DOI
10.1038/mp.2016.127
